Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glycerol for Middle Ear OCT Visualization
NCT05497934Phase 1Withdrawn
- Sponsor
- Nova Scotia Health
- Start
- Oct 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of Miniderm, sponsored by Nova Scotia Health. Primary endpoint: Change in optical attenuation rate of the tympanic membrane at 20 minutes. Planned start Oct 2022; status: withdrawn.
02
Drugs
Miniderm
Beyond the preview
Go deeper on NCT05497934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05497934.